Phase 1/2 SLO-RP trial completed target enrollment of 48 pat…
News
July, 29 2021 • Articles
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
July 29th, 2021 - Source: Inside Philanthropy
Since its establishment in 1971 by a group of families affected by retinal disease, the Foundation Fighting Blindness has funded research into several of the most serious and common of these conditions, like macular degeneration and retinitis pigmentosa. The foundation grew to become the leading private funder of basic research into conditions that cause blindness and vision loss for more than 10 million Americans and millions more worldwide. In its 50 years in operation, the foundation has raised over $816 million to support research—including the identification of key genes linked to retinal diseases—that has enabled the launch of dozens of clinical trials to test possible treatments. All in all, a solid track record.
Click here for the rest of the article
- First oral presentation on SPVN20 in a major scientific and…
ATSN-201 leverages AAV capsid that spreads laterally beyond …
Paris, April 27, 2023 – SparingVision (“the Company”), a cli…
ATSN-101 demonstrated clinically meaningful improvements in …
Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to joi…
The investment supports the clinical development of two nove…
Opus to advance preclinical development programs for BEST1- …
SparingVision set to advance into the clinic with breakthrou…
OPGx-001 is Opus’ first program to enter clinical evaluation…
Uni-Rare Study will improve clinical understanding of more I…
Managing director of the Retinal Degeneration Fund joins boa…